Study Title: A Phase 3 Open-Label, Randomized Study of PDS0101 Plus Pembrolizumab vs. Pembrolizumab Alone in First Line Treatment of Immune Checkpoint Inhibitor (ICI) Naive Subjects with Unresectable Recurrent and/or Metastatic (R/M) Human Papillomavirus 16 (HPV16)-Related Head and Neck Squamous Cell Carcinoma (HNSCC)
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Kaczmar, John, at kaczmar@musc.edu, or please call +1 843-792-6691.Study Coordinator, Avinger, Madison, at avingerm@musc.edu.Trial opened at the following institutions: Medical University of South Carolina